title: Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
abstract: BACKGROUND
  Unlike novel molecular-targeted therapies for metastatic gastrointestinal stromal tumors (GIST), conventional treatments for peritoneal sarcomatosis (PS) are mostly ineffective. As with carcinomatosis of epithelial origin, a rationale base supports an aggressive locoregional treatment of PS, but the use of CRS and HIPEC in this setting is still controversial. We assessed the outcome of clinically and pathologically homogeneous subsets of patients with PS uniformly treated by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
  
  
  METHODS
  A prospective database of 37 patients who underwent CRS and close-abdomen HIPEC with cisplatin and doxorubicin or mitomycin-C was reviewed. PS originated from GIST (pre-imatinib era) in 8 patients, uterine leiomyosarcoma (ULS) in 11, retroperitoneal liposarcoma (RPLP) in 13, and other sarcoma in 5.
  
  
  RESULTS
  CRS was macroscopically complete in 28 patients (75.7%). Operative mortality was 3.7% and morbidity 21.6%. After median follow-up of 104 (range, 1-131) months, peritoneal disease progression occurred in 16 patients, distant metastases in 5, and both in 13. For all patients, median overall survival was 26.2 months; 7 patients were alive at 46-130 months (ULS, n = 4; RPLP, n = 2; GIST, n = 1). RPLP had the best overall survival (median, 34 months) but 100% peritoneal relapse; GIST had dismal overall, local-regional-free and distant-free survival; ULS had the higher proportion of long survivors and best local-regional-free survival.
  
  
  CONCLUSIONS
  Overall, results of CRS and HIPEC did not compare favorably to those of conventional therapy. In a subgroup analysis, the combined approach did not change GIST and RPLS natural history. The interesting results with ULS may warrant further investigations.
authors.affiliation: Peritoneal Malignancy Program, Department of Surgery, National Cancer Institute, Milan, Italy.
authors.forename: Dario
authors.initials: D
authors.lastname: Baratti
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Pennacchioli
authors.forename: Shigeki
authors.initials: S
authors.lastname: Kusamura
authors.forename: Marco
authors.initials: M
authors.lastname: Fiore
authors.forename: Maria Rosaria
authors.initials: MR
authors.lastname: Balestra
authors.forename: Chiara
authors.initials: C
authors.lastname: Colombo
authors.forename: Elvira
authors.initials: E
authors.lastname: Mingrone
authors.forename: Alessandro
authors.initials: A
authors.lastname: Gronchi
authors.forename: Gronchi
authors.initials: G
authors.lastname: Alessanrdro
authors.forename: Marcello
authors.initials: M
authors.lastname: Deraco
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D010478:Chemotherapy, Cancer, Regional Perfusion; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007890:Leiomyosarcoma / Q000145:classification / Q000473:pathology / Q000628:therapy*; D008080:Liposarcoma / Q000145:classification / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009367:Neoplasm Staging; D010534:Peritoneal Neoplasms / Q000145:classification / Q000473:pathology / Q000628:therapy*; D011446:Prospective Studies; D012186:Retroperitoneal Neoplasms / Q000145:classification / Q000473:pathology / Q000628:therapy; D015996:Survival Rate; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000145:classification / Q000473:pathology / Q000628:therapy*; D055815:Young Adult
chemical_list: D016685:Mitomycin; D004317:Doxorubicin; D002945:Cisplatin